Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer.

Xun-Xi LuZongchao GouHong ChenLi LiFei ChenChunjuan BaoHong Bu

Published in: Journal for immunotherapy of cancer (2024)

Our IP model shows favorable performance in predicting NACI response and is an effective tool for identifying BC patients who will benefit from ICIs. It may help clinicians optimize treatment strategies and guide clinical decision-making.

Keyphrases

decision making
rectal cancer
lymph node
palliative care
squamous cell carcinoma
locally advanced
gene expression
radiation therapy
dna methylation
transcription factor
young adults
genome wide identification
childhood cancer